Ability Pharmaceuticals 

AbilityPharma is a late stage company developing clinically (Phase 2) an oral targeted anti-cancer drug (ABTL0812)

OWNER

Carles Domènech (See Profile)


OWNER

Sergi Serrano (See Profile)


Sector

Cancer therapeutics

Stage

Development, market readiness, clinical trial

Country

Spain


Low toxicity and preclinical efficacy make ABTL0812 an excellent candidate for pediatric cancers

ABTL0812 is in phase 2b clinical trials as a first line therapy for pancreatic cancer

ABTL0812 increases survival and decreases relapse rate by increasing the efficacy of chemotherapy

Phase 2a trials for endometrial and lung cancer completed for ABTL812 with very positive results

Status

Approved

IP Type

Patent

Time

12 years

Countries

France
Israel
Spain
USA

Coverage

ABTL0812, the first drug candidate in a phase 2b clinical trial

Know more of this patent

View more

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 2nd of July 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar